Drug: Bavencio (Avelumab, EMD Serono)
Status: Approved for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy
Significant Information:
- Targets the PD-1/PD-L1 pathway
- Based on data from the Phase II JAVELIN Merkel 200 study
- Of the 88 patients who received avelumab in the trial, 33% experienced complete or partial shrinkage of their tumors
- The response lasted for more than 6 months in